The fusion of AI breakthroughs, policy shifts, and innovative therapies make it clear that the life sciences industry stands on the brink of a new era. In the U.S., the landscape is especially dynamic, with the Inflation Reduction Act and revisions to the R&D tax framework stirring investor sentiment. How will the industry secure the capital and resources it needs for continuous innovation?